[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Wrotek S., Sobociska J., Kozowski H.M., Pawlikowska M., Jdrzejewski T., Dzialuk A
While 12 weeks of treatment at 4 mg or 6 mg was safe, it was insufficient to produce a statistically significant difference in weight loss compared with placebo
Assessments included laboratory testing, body composition analysis via bioelectrical impedance, and two validated questionnaires: the Food Frequency Questionnaire (FFQ) and the Japanese version of the Dutch Eating Behavior Questionnaire (DEBQ-J) ( Clinical characteristics were summarized as mean and SD for continuous variables and frequencies for categorical variables
With respect to lowering of body weight, a significant dose-dependent effect was evident with tirzepatide even when compared with the GLP-1 RAs semaglutide and dulaglutide
Other medications, like Wegovy, are not subsidised
These medications stimulate insulin production, reduce appetite, and lower blood sugar levels after meals